An $11.5M Series C will help Gliknik advance 3 treatments for cancer, autoimmune disease

Add a company based in Baltimore’s University of Maryland BioPark to this week’s Money Moves.

Gliknik, a company developing treatments for people with cancer and autoimmune diseases, announced completion of its Series C round.

The company raised $11.5 million in a round led by First in Ventures (FIV). Also participating were SAISO Partners, and affiliates of RDA Ventures and Garden Street Holdings.

“We believe that Gliknik has created several potential best-in-class mid-stage assets,” said Scott Roth, managing partner of FIV, in a statement. “This capital will help unlock the potential of these compounds and uniquely positions Gliknik to make a difference for patients with cancer or autoimmune disorders.”

The funding will help the company progress on trial work for three of its treatments in development. They include:

• biropepimut-S, which is in a clinical trial phase. This is designed for high-risk squamous cell cancer of the oral cavity.
• GL-2045, which treats autoimmune diseases. It is under development by Pfizer, to which Gliknik licensed technology.
• GL-0719, which is “designed to control diseases while leaving critical host systems intact,” the company said in a statement. It is slated for a clinical trial in 2021.

The company also has additional treatments in its pipeline that the funding will help develop.

In all, 14-year-old Gliknik has now raised $81 million in funding. The company is among a group of businesses developing new kinds of therapeutics and treatments for diseases that are clustered around the city’s health and research institutions.